News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Tom Powles: New ESMO’s guidlines for advanced bladder cancer Annals of Oncology – Enforumab Vedotin and pembrolizumab is the new standard of care
Photo from Tom Powles/Twitter
Mar 17, 2024, 19:51

Tom Powles: New ESMO’s guidlines for advanced bladder cancer Annals of Oncology – Enforumab Vedotin and pembrolizumab is the new standard of care

Tom Powles, Director of Barts Cancer Center, shared a post on X:

“New ESMO’s guidelines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin and pembrolizumab is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant.”

Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care   Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care

View the article.
Source: Tom Powles/X

Annals of Oncology Barts Cancer Center bladder cancer cancer Enforumab Vedotin ESMO OncoDaily Oncology pembrolizumab Platinum therapy Tom Powles
Special Coverage
Science
Jan 16, 2025, 09:48
Sarbajit Mukherjee: Excited to share my 50th publication from Roswell Park
Insight
Jan 16, 2025, 09:37
Laura Bukavina: Age doesn't limit EV efficacy
Blog
Jan 16, 2025, 09:28
Glenn J. Hanna: Multidisciplinary approach to treat HPV-driven oropharyngeal cancer
Societies
Jan 16, 2025, 09:23
A look back on 2024 MCI Precision Oncology - Miami Cancer Institute Research
Societies
Jan 16, 2025, 09:17
MD Anderson has received a $10 million gift to support Be Well Beaumont initiative
Science
Jan 16, 2025, 09:12
Erman Akkus: TACE plus+ treatments in Hepato-Cellular Carcinoma
Dialogues
Jan 16, 2025, 09:08
Hope, Research, and Advocacy: Paving the Way to a Cure
Insight
Jan 16, 2025, 08:54
Financial Toxicity in Oncology: Impact and Proposed Solutions in JCO Oncology Practice
Insight
Jan 16, 2025, 08:49
EORTC meta-analysis: Progression-free survival as surrogate in advanced cervical carcinoma
Insight
Jan 16, 2025, 08:42
Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC
Career
Jan 16, 2025, 08:14
Narjust Florez was named as a health equity champion by Boston Business Journal
Blog
Jan 16, 2025, 07:14
Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications